Medimabs/HIV-1 (CD4bs (gp120)) Human Monoclonal Antibody (654-30D)/100 µg/MM-0255-P,Medimabs,,Medimabs,Medimabs inc,+,,Array.Array.Array蚂蚁淘厂家直采.

产品名称：Medimabs/HIV-1 (CD4bs (gp120)) Human Monoclonal Antibody (654-30D)/100 µg/MM-0255-P

产品编号：MM-0255-P

市场价：¥10100.00

场地：美国(厂家直采)

产品分类：抗体类>一抗>单克隆抗体>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：$505.00

品牌： Medimabs

公司：Medimabs inc.

公司分类：

商品介绍

Target:

HIV-1 (CD4bs (gp120))

Target background:

Of the two types of Human immunodeficiency virus (HIV) which have been characterized, HIV-1 is more infective and is prevalent globally. The HIV virion is encapsulated by a viral envelope that contains complexes of surface proteins including glycoprotein 120 (gp120), which are important for the virus to attach and fuse to infect target cells. The glycoprotein CD4 (cluster of differentiation 4), found on the surface of T-cells, interacts with gp120 and cytokine receptors to mediate the entry of the virus into cells. This antibody, 654-30D, has been shown to neutralize HIV-1.

Immunogen:

This antibody was generated from HIV-infected individuals by a method based on the Epstein-Barr virus transformation of peripheral blood mononuclear cells (PBMCs) followed by fusion with heteromyeloma cells. The epitope for this antibody is discontinuous.

Specificity: The antibody recognizes the CD4 binding domain of the HIV-1 protein gp120.

Clone ID:

654-30D

Isotype:

IgG1 lambda

Preservative:

None

Format:

Lyophilized protein G purified in PBS pH7.4

Recommend starting dilution:

Reconstitute with deionized water. Optimal dilution has to be determined by the user.

Limitations:

Research Use Only

References:

1.-Li L - Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.

2.-Gorny MK - Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from...

3.-Jeffs SA - Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

4.-Gorny MK - Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.

5.-Nyambi PN - Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

6.-Gorny MK - A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.

7.-Nyambi PN - Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness ...

8.-Hioe CE - Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

9.-Gorny MK - Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

10.-Stamatatos L - Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 in...

11.-Zolla-Pazner S - Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.

12.-Laal S - Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.

13.-Gorny MK - Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.

Storage:

Lyophilized antibodies can be kept at 4ºC for up to 3 months and should be kept at -20ºC for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80ºC) or kept at 4ºC for short-term usage (2 months). For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy.

品牌介绍

Medimabs麦吉尔大学的一组研究人员于2006年在魁北克蒙特利尔成立，以确保本地研究人员能够以负担得起的价格获得最新的高质量研究抗体。我们的目标是提供定制抗体生成服务，并提供比大多数研究实验室自己能做的更好，更快和更便宜的服务。

截至2018年，我们的设施现在位于蒙特利尔的中心，周围是蒙特利尔的生命科学集群，周围有许多生物技术公司，大学，研发机构，主要的主要医疗保健网络和医院。新的场所，但公司的重点仍然保持不变，因为它具有提供新的创新服务和可满足您所有抗体需求的完整“一站式服务”的额外好处。

公司介绍

产品分类

更多...